Anton Xavier is the Founder and CEO of K9 Biotech, a pre-clinical comparative oncology venture focused on treating similar cancers in pet dogs and humans.
Anton Xavier is also the Assistant Director at the NY State Center for Biotechnology where he focuses on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners in NY State.
Prior to founding K9 Biotech, Anton was at Pfizer where he had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications.
Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.